ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,881 to 4,900 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Palbociclib vs Placebo: serious adverse events64 of 633

65 of 611

-0.5 points

-4.0 to 2.9

1,244NCT01864746

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Nadroparin vs Fondaparinux: Number of Participants With Confirmed VTE and Death up to the Final Visit or Contact49 of 622

15 of 621

5.5 points

3.0 to 8.0

1,243NCT00843492

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

Multilevel Intervention vs Control: deaths from any cause5 of 627

4 of 614

0.1 points

-1.0 to 1.3

1,241NCT03683173

Promoting Physical Activity in Rural Communities

Vandetanib vs Erlotinib: Objective Response Rate (ORR)75 of 623

74 of 617

0.0 points

-3.6 to 3.7

1,240NCT00364351

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Vandetanib vs Erlotinib: Disease Control Rate (DCR)254 of 623

242 of 617

1.5 points

-3.9 to 7.0

1,240NCT00364351

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants Free From Recurrent Atrial Fibrillation (AF) Following the 90 Day Blanking Period305 of 611

437 of 629

-19.6 points

-24.8 to -14.1

1,240NCT00911508

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Naldemedine vs Placebo: serious adverse events60 of 621

73 of 619

-2.1 points

-5.6 to 1.3

1,240NCT01965652

Long Term Safety of Naldemedine

Vandetanib vs Erlotinib: serious adverse events197 of 623

155 of 614

6.4 points

1.3 to 11.4

1,237NCT00364351

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Identifying Cost of Care or Medications as BP Care Burden at Six Months188 of 649

134 of 588

6.2 points

1.3 to 11.0

1,237NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

PREP (Potentially Reduced Exposure Product) Group vs Cigarette Group: serious adverse events3 of 626

3 of 610

-0.0 points

-1.0 to 1.0

1,236NCT01509586

A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco

Motavizumab (MEDI-524) vs Palivizumab: The Number of Subjects Hospitalized for RSV Infection.12 of 623

16 of 612

-0.7 points

-2.5 to 1.0

1,235NCT00538785

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide: Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)115 of 615

50 of 620

10.6 points

6.9 to 14.4

1,235NCT03834493

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide: Number of Participants Who Experience an Adverse Event (AE)594 of 615

596 of 620

0.5 points

-1.7 to 2.6

1,235NCT03834493

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Seropositive Participants Within Each Treatment Arm Who Experience B/Yamagata Strain-specific Seroresponse Post Dose.52 of 983

13 of 249

0.1 points

-3.6 to 2.7

1,232NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a B/Yamagata Strain-specific HAI Antibody Titer ≥ 32 Post Dose.837 of 983

215 of 249

-1.2 points

-5.6 to 4.1

1,232NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Without Hepatic Dysfunction vs With Hepatic Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.14 of 1,087

2 of 145

-0.1 points

-3.6 to 1.2

1,232NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

EEG Guided Protocol vs Control Arm: deaths from any cause4 of 614

20 of 618

-2.6 points

-4.3 to -1.1

1,232NCT02241655

Electroencephalography Guidance of Anesthesia

EEG Guided Protocol vs Control Arm: serious adverse events124 of 614

130 of 618

-0.8 points

-5.4 to 3.7

1,232NCT02241655

Electroencephalography Guidance of Anesthesia

Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events234 of 622

201 of 610

4.7 points

-0.7 to 10.0

1,232NCT02753127

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Without Renal Dysfunction vs With Renal Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.14 of 1,123

2 of 108

-0.6 points

-5.3 to 1.0

1,231NCT01107743

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=245"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=245

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01864746-sae",
        "title": "Palbociclib vs Placebo: serious adverse events",
        "summary": "64 of 633 against 65 of 611; risk difference -0.5 points, 95% interval -4.0 to 2.9; NCT01864746, A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery",
        "record": "/library/comparisons/NCT01864746-sae",
        "nct_id": "NCT01864746",
        "kind": "serious-adverse-events",
        "participants": 1244,
        "risk_difference": {
          "value": -0.005277133541729692,
          "lower": -0.0395270897918196,
          "upper": 0.02876161055165794
        },
        "group_1": "64 of 633",
        "group_2": "65 of 611",
        "difference": "-0.5 points",
        "interval": "-4.0 to 2.9",
        "trial_title": "A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery"
      },
      {
        "id": "NCT00843492-2bf69023",
        "title": "Nadroparin vs Fondaparinux: Number of Participants With Confirmed VTE and Death up to the Final Visit or Contact",
        "summary": "49 of 622 against 15 of 621; risk difference 5.5 points, 95% interval 3.0 to 8.0; NCT00843492, A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery",
        "record": "/library/comparisons/NCT00843492-2bf69023",
        "nct_id": "NCT00843492",
        "kind": "outcome",
        "participants": 1243,
        "risk_difference": {
          "value": 0.05462354567625084,
          "lower": 0.03047025552051431,
          "upper": 0.0802813345694991
        },
        "group_1": "49 of 622",
        "group_2": "15 of 621",
        "difference": "5.5 points",
        "interval": "3.0 to 8.0",
        "trial_title": "A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=246",
  "request_id": "7RMo5FEWy1qnjKQA"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?